<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430040</url>
  </required_header>
  <id_info>
    <org_study_id>1918</org_study_id>
    <nct_id>NCT00430040</nct_id>
  </id_info>
  <brief_title>Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.</brief_title>
  <official_title>Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI:Effects on Oxidative Stress and Inflammation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaleida Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are&#xD;
      receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to&#xD;
      treatment with Lisinopril alone.It is believed that carvedilol provides added benefits by&#xD;
      suppressing free radicals(charged substances that cause damage to the body ) and&#xD;
      inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is an atherosclerotic, pro-inflammatory and pro-oxidative stress.Both&#xD;
      vascular oxidative stress and inflammation are CVD risk factors and impact endothelial&#xD;
      function.&#xD;
&#xD;
      Carvedilol has been demonstrated in preclinical and clinical studies (although limited in&#xD;
      size) to exert anti-inflammatory and antioxidant properties: (1) reduce the inflammation&#xD;
      markers such as high sensitivity C-reactive protein (hsCRP); (2) reduce oxidative stress via&#xD;
      dually eliminating existing reactive oxygen species (ROS) and suppressing the generation of&#xD;
      ROS; (3) prevent lipid peroxidation in myocardial cell membrane; (4) protect endothelial and&#xD;
      vascular muscle cells from oxygen radical-mediated injury.&#xD;
&#xD;
      This project is about studying the effect of carvedilol CR on blood vessels of diabetic&#xD;
      hypertensive patients as compared to Lisinopril alone.&#xD;
&#xD;
      This study involves weaning patient off their current antihypertensive medications and&#xD;
      starting them on Lisinopril and Carvedilol CR or placebo for 6 months and studying the&#xD;
      effects of the drugs during this period and thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial artery vascular reactivity at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Brachial artery vascular reactivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress in Mononuclear cells, serum and plasma at six months</measure>
    <time_frame>6 months</time_frame>
    <description>Oxidative stress</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carvedilol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lisinopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lisinopril</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol</intervention_name>
    <description>carvedilol</description>
    <arm_group_label>carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisinopril</intervention_name>
    <description>lisinopril</description>
    <arm_group_label>lisinopril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is male or female &gt;= 18 and &lt;= 70 years of age&#xD;
&#xD;
          -  Has a documented history of type 2 diabetes mellitus for a minimum of four months&#xD;
             prior to the screening visit&#xD;
&#xD;
          -  Has a documented history of or current presentation with Stage 1 or Stage 2&#xD;
             hypertension and meets one of the following criteria:&#xD;
&#xD;
          -  Has controlled hypertension (sSBP &lt;130 mmHg AND sDBP &lt;80 mmHg) on &gt;=2 antihypertensive&#xD;
             medications NOTE: A combination drug containing two antihypertensive agents represents&#xD;
             two antihypertensive medications OR&#xD;
&#xD;
          -  Has uncontrolled hypertension (sSBP &gt;=130 and &lt;=170 mmHg AND/OR sDBP &gt;=80 and &lt;=105&#xD;
             mmHg) on one or two antihypertensive medications OR&#xD;
&#xD;
          -  Has newly diagnosed or previously untreated hypertension (sSBP &gt;=130 and &lt;=170 mmHg&#xD;
             AND/OR sDBP &gt;=80 and &lt;=105 mmHg&#xD;
&#xD;
          -  At Randomization, sitting systolic blood pressure (sSBP) &gt;= 130 mmHg or sitting&#xD;
             diastolic blood pressure (sDBP) &gt;= 80 mmHg and sSBP &lt;= 170 mmHg and sDBP &lt;= 105 mmHg&#xD;
&#xD;
          -  Has been on a stable dose of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)&#xD;
             reductase inhibitor (statin) for a minimum of four months prior to the screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has any clinically significant abnormality identified in the screening physical&#xD;
             examination, laboratory tests or electrocardiogram which, in the judgement of the&#xD;
             investigator, would preclude safe completion of the study&#xD;
&#xD;
          -  Is female of childbearing potential&#xD;
&#xD;
          -  Has any of these cardiac conditions: uncontrollable or symptomatic arrhythmias,&#xD;
             unstable angina, sick sinus syndrome or second or third degree heart block (unless&#xD;
             treated with a permanent, functioning pacemaker), bradycardia (heart rate &lt;55 bpm),&#xD;
             and stroke within three months of study screening, and history of myocardial&#xD;
             infarction.&#xD;
&#xD;
          -  Has Congestive Heart Failure NYHA (New York Heart Association) class II-IV&#xD;
&#xD;
          -  Has type 1 diabetes mellitus&#xD;
&#xD;
          -  Has newly diagnosed type 2 diabetes (within 4 months of screening visit)&#xD;
&#xD;
          -  Has HbA1c &gt; 8.5%&#xD;
&#xD;
          -  Has the following, as it relates to subject's antidiabetic therapy:Initiated or&#xD;
             changed dosage or formulation of thiazolidinediones (TZDs) within 6 months of&#xD;
             screening visit.&#xD;
&#xD;
          -  A history of acute or chronic acidosis, including diabetic ketoacidosis&#xD;
&#xD;
          -  Has current clinical diagnosis of chronic obstructive pulmonary disease (COPD, e.g.,&#xD;
             chronic bronchitis) or asthma&#xD;
&#xD;
          -  Has a history of bronchospastic disease not undergoing active therapy in whom, in the&#xD;
             investigator's opinion, treatment with study medication could provoke bronchospasm&#xD;
&#xD;
          -  Has evidence of any of the following clinically significant diseases that could impair&#xD;
             the absorption, metabolism, or excretion of orally-administered medication:&#xD;
&#xD;
          -  renal disease defined as estimated Glomerular Filtration Rate (eGFR) &lt;60mL/min per&#xD;
             1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula below: GFR&#xD;
             (mL/min/1.73m2) = 186 x [Serum Creatinine (umol/L) x 0.0113]-1.154 x Age(years)-0.203&#xD;
             (x 0.742 if female)&#xD;
&#xD;
          -  hepatic disease (i.e., ALT or AST levels greater than three times the upper limit of&#xD;
             normal range, history of hepatic impairment, or by clinical assessment)&#xD;
&#xD;
          -  Chronic biliary disorders&#xD;
&#xD;
          -  Has endocrine disorders (e.g., pheochromocytoma, active and untreated hypo or&#xD;
             hyperthyroidism)&#xD;
&#xD;
          -  Has any known contraindication to ACE inhibitors, alpha- or beta-blocker treatment&#xD;
&#xD;
          -  Has systemic disease, including cancer, with reduced (&lt;12 months) life expectancy&#xD;
&#xD;
          -  Has used an investigational drug within 30 days or 5 half-lives (whichever is longer)&#xD;
             preceding the first dose of study medication&#xD;
&#xD;
          -  Has a history of a psychological illness or any condition that would interfere with&#xD;
             the subject's ability to understand or complete the requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaleida Health / University at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes - Endocrinology Center of Western New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaleida Health</investigator_affiliation>
    <investigator_full_name>Paresh Dandona, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Carvedilol CR</keyword>
  <keyword>Beta-blocker</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Vascular benefits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

